BD, Lab21 Team on Oncology Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today said that its BD Diagnostics unit will collaborate with Lab21 on the development of oncology assays to run on the BD Max molecular diagnostic system.

Cambridge, UK-based Lab21 will develop PCR-based tests for a series of oncology markers, while BD will be responsible for manufacturing and commercializing the tests worldwide. The Franklin Lakes, NJ-based medical products and research tools firm said that the first two assays developed under the collaboration will target KRAS and BRAF mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.